Plain-English translation of NCT06730828 on ClinicalTrials.gov ↗ ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called amiodarone-infused CardiaMend patches—special patches placed directly on the heart during open-heart surgery. About one in four patients who have open-heart surgery develop an irregular heart rhythm (atrial fibrillation) afterward, which can cause serious problems like stroke and extended hospital stays. This study wants to see if these medicated patches are safe and whether they might prevent this complication from developing.
Irregular heartbeat after open-heart surgery is very common and can lead to dangerous complications and longer recoveries. Doctors need a safe, effective way to prevent this problem right at the time of surgery, before it starts.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will receive open-heart surgery as planned. During your surgery, your surgical team will place special medicated patches directly on your heart—either with no patches (control group), patches with a lower dose of medication, or patches with a higher dose. The patches will be left in place and will naturally dissolve over time. After surgery, you will be monitored for any side effects or complications. The study team will follow up with you to track whether you develop irregular heartbeat and to assess the safety of the treatment.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States